BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Front Neurosci 2020;14:785. [PMID: 32848559 DOI: 10.3389/fnins.2020.00785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
2 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106550] [Reference Citation Analysis]
3 Zhou KQ, Dhillon SK, Bennet L, Gunn AJ, Davidson JO. Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy-Is Exendin-4 the Answer? Int J Mol Sci 2022;23:10191. [PMID: 36077587 DOI: 10.3390/ijms231710191] [Reference Citation Analysis]
4 Fu J, Zhao X, Tian F, Yu X. Continuous dopaminergic stimulation counteracts L-DOPA-induced overactivity of Ca2+ in 6-OHDA-lesioned rats. Exp Brain Res 2022. [PMID: 35699744 DOI: 10.1007/s00221-022-06390-y] [Reference Citation Analysis]
5 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim MM, Alshehri S, Mustafa G, Ahmad J, Alhakamy NA, Mishra A. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Front Pharmacol 2022;13:805388. [DOI: 10.3389/fphar.2022.805388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Shkodina AD, Tan SC, Hasan MM, Abdelgawad M, Chopra H, Bilal M, Boiko DI, Tarianyk KA, Alexiou A. Roles of clock genes in the pathogenesis of Parkinson's disease. Ageing Res Rev 2022;74:101554. [PMID: 34973458 DOI: 10.1016/j.arr.2021.101554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
8 Shkodina AD, Tan SC, Hasan MM, Abdelgawad M, Chopra H, Bilal M, Boiko DI, Tarianyk KA, Alexiou A. Roles of clock genes in the pathogenesis of Parkinson's disease. Ageing Research Reviews 2022;74:101554. [DOI: 10.1016/j.arr.2021.101554] [Reference Citation Analysis]
9 Elabi OF, Davies JS, Lane EL. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease. Int J Mol Sci 2021;22:12346. [PMID: 34830228 DOI: 10.3390/ijms222212346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. J Neurochem 2021. [PMID: 34569615 DOI: 10.1111/jnc.15521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shang P, Baker M, Banks S, Hong SI, Choi DS. Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists. J Mov Disord 2021;14:193-203. [PMID: 34399565 DOI: 10.14802/jmd.21035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Labandeira CM, Fraga-Bau A, Arias Ron D, Muñoz A, Alonso-Losada G, Koukoulis A, Romero-Lopez J, Rodriguez-Perez AI. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists. Front Neuroendocrinol 2021;62:100914. [PMID: 33845041 DOI: 10.1016/j.yfrne.2021.100914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
13 Jung YJ, Tweedie D, Scerba MT, Kim DS, Palmas MF, Pisanu A, Carta AR, Greig NH. Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Front Neurosci 2021;15:656921. [PMID: 33854417 DOI: 10.3389/fnins.2021.656921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]